Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more 2015 The Lancet Oncology 1406 citations